Exarafenib
As of the edition of 20 October 2026, Exarafenib is a small molecule: in active development; acts on RAF1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer; Hormones; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pierre Fabre | Lead sponsor of trials | 2021 to now |